PHOTODYNAMIC THERAPY OF MACULAR DEGENERATION

  • Davorin Sevšek Očesna klinika Klinični center Zaloška 29/A 1525 Ljubljana
  • Vladimir Debelić Očesna klinika Klinični center Zaloška 29/A 1525 Ljubljana
  • Aleksandra Kraut Očesna klinika Klinični center Zaloška 29/A 1525 Ljubljana
  • Mojca Urbančič Očesna klinika Klinični center Zaloška 29/A 1525 Ljubljana
Keywords: macular degeneration, choroidal neovascularisation, photodynamic therapy, verteporfin

Abstract

Background. University Eye Clinic in Ljubljana began to perform a photodynamic therapy (PDT) in July 2002. Up to September 2003 there were 51 PDT interventions on 36 eyes. Almost half of the eyes had one or more reinterventions. PDT was used on 29 eyes with age related macular degeneration (AMD). Just before the treatment all of them had visual acuity (VA) 6/60 or better and there were predominantly classical or classical choroidal neovascular (CNV) membranes. Most VA did not changed significantly in follow-up visits but diameter of CNV membranes was obviously reduced. In macular degeneration due to pathologic myopia (MMD), photodynamic therapy was performed on 7 eyes with mainly occult CNV and VA was 12/60 or better. VA was mostly better in follow-up visits than before treatment with PDT.

Conclusions. There were no serious complications during and after PDT interventions. Two patients had back pain during the infusion of Verteporfin but there was no need to stop the intervention.

Downloads

Download data is not yet available.

References

Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-years results of 2 randomized clinical trials – TAP report 2. Arch Ophthalmol 2001; 119: 198–207.

Anon. Verterporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two years results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in photodynamic therapy. Am J Ophthalmol 2001; 131: 541–60.

Anon. Guidelines for using verteporfin in photodynamic therapy to treat choroidal neovascularization due to age-relating macular degeneration and other cause. Retina 2002; 22: 6–18.

Anon. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3. Ophthalmology 2003; 110: 667–73.

Schmidt-Erfurth U, Miller JW, Sikenberg M et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related degeneration. Results of retreatments in a phasae 1 and 2 study. Arch Ophthalmol 1999; 117: 1177–87.

Sikenberg M, Schmidt-Erfurth U, Miller JW et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. arch ophthalmol. 2000; 118: 327–36.

Anon. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials – TAP report. Treatment of age-related macular degeneration with photodynamic therapy. Arch Ophthalmol 1999; 117: 1329–45.

Soucek P. PDT with verteporfin in predominantly classic subfoveal CNV in age-related and myopic macular degeneration. Acta Photodynamica 2003; 1: 6–13.

Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol 2001; 85: 483–95.

Schachat A. How to perform PDT with visudyne. In: Photodynamic Therapy Leaders Symposium. Vienna. Ocular Surgery News, 1999: 4–8.

Kanski JJ. Age-related macular degeneration. In: Kanski JJ. Clinical ophthalmology. London: Butterworths, 1989: 349–55.

How to Cite
1.
Sevšek D, Debelić V, Kraut A, Urbančič M. PHOTODYNAMIC THERAPY OF MACULAR DEGENERATION. TEST ZdravVestn [Internet]. 1 [cited 5Aug.2024];73(5). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2315
Issue
Vol 73 No 5 (2004): May
Section
Professional Article


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.